|
G |
G6pdx |
glucose-6-phosphate dehydrogenase X-linked |
increases activity |
ISO |
Methylphenazonium Methosulfate results in increased activity of G6PD protein |
CTD |
PMID:1901343 |
|
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
increases activity |
ISO |
Methylphenazonium Methosulfate results in increased activity of PGD protein |
CTD |
PMID:1901343 |
|
NCBI chr 4:149,234,448...149,251,162
Ensembl chr 4:149,234,448...149,251,228
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
decreases activity multiple interactions |
ISO |
Atazanavir Sulfate results in decreased activity of ABCB11 protein Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:24014644 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
increases transport multiple interactions |
ISO |
ABCB1 protein results in increased transport of Atazanavir Sulfate [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA |
CTD |
PMID:29859254 PMID:33819548 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
decreases expression |
ISO |
Atazanavir Sulfate results in decreased expression of ABCC2 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
decreases expression |
ISO |
Atazanavir Sulfate results in decreased expression of ABCC3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:46,924,214...46,989,088
Ensembl chr 8:46,924,074...46,989,088
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:95,701,321...95,740,836
Ensembl chr 8:95,701,379...95,740,845
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:138,121,217...138,138,444
Ensembl chr 3:138,121,227...138,136,653
|
|
G |
Adh6b |
alcohol dehydrogenase 6B (class V) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:138,047,176...138,064,621
Ensembl chr 3:138,047,536...138,064,622
|
|
G |
Akr1c6 |
aldo-keto reductase family 1, member C6 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1C4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr13:4,484,354...4,507,529
Ensembl chr13:4,484,305...4,507,876
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:37,506,913...37,551,856
Ensembl chr 6:37,507,108...37,545,750
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
Atazanavir Sulfate binds to ALB protein [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA |
CTD |
PMID:15814459 PMID:16336266 PMID:33819548 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:110,367,291...110,411,612
Ensembl chr 7:110,367,413...110,411,612
|
|
G |
Apoa1 |
apolipoprotein A-I |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
Atazanavir Sulfate results in increased expression of ATF4 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression multiple interactions |
ISO |
Atazanavir Sulfate results in increased expression of ATF6 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions increases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA Atazanavir Sulfate results in increased expression of ATG7 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575
|
|
G |
Atp8b1 |
ATPase, class I, type 8B, member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:64,662,050...64,794,342
Ensembl chr18:64,662,038...64,794,338
|
|
G |
Baat |
bile acid-Coenzyme A: amino acid N-acyltransferase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:49,489,416...49,507,915
Ensembl chr 4:49,489,422...49,506,557
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA Atazanavir Sulfate results in decreased expression of CAT mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Atazanavir Sulfate results in increased expression of CCL2 protein |
CTD |
PMID:17668557 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
ISO |
Atazanavir Sulfate results in increased expression of CCL3 protein |
CTD |
PMID:17668557 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:134,109,894...134,117,769
Ensembl chr 1:134,109,914...134,117,919
|
|
G |
Csf1 |
colony stimulating factor 1 (macrophage) |
increases expression multiple interactions |
ISO |
Atazanavir Sulfate results in increased expression of CSF1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cttn |
cortactin |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:143,989,468...144,024,743
Ensembl chr 7:143,989,470...144,024,746
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CXCL8 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cyld |
CYLD lysine 63 deubiquitinase |
increases expression multiple interactions |
ISO |
Atazanavir Sulfate results in increased expression of CYLD mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 8:89,423,506...89,478,574
Ensembl chr 8:89,423,675...89,478,573
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051
|
|
G |
Cyp2a5 |
cytochrome P450, family 2, subfamily a, polypeptide 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2A6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
decreases expression multiple interactions |
ISO |
Atazanavir Sulfate results in decreased expression of CYP2B6 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2c38 |
cytochrome P450, family 2, subfamily c, polypeptide 38 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519
|
|
G |
Cyp2c52-ps |
cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Atazanavir Sulfate results in decreased expression of CYP7A1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
|
|
G |
Cyp7b1 |
cytochrome P450, family 7, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:18,126,108...18,298,054
Ensembl chr 3:18,126,114...18,297,502
|
|
G |
Cyp8b1 |
cytochrome P450, family 8, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA Atazanavir Sulfate results in increased expression of DDIT3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:44,252,680...44,256,851
Ensembl chr12:44,252,342...44,257,109
|
|
G |
Dnajc10 |
DnaJ heat shock protein family (Hsp40) member C10 |
multiple interactions increases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA Atazanavir Sulfate results in increased expression of DNAJC10 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:80,145,790...80,184,399
Ensembl chr 2:80,145,810...80,184,387
|
|
G |
Dnajc12 |
DnaJ heat shock protein family (Hsp40) member C12 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:63,218,222...63,244,619
Ensembl chr10:63,218,222...63,246,355
|
|
G |
Dnajc9 |
DnaJ heat shock protein family (Hsp40) member C9 |
increases expression |
ISO |
Atazanavir Sulfate results in increased expression of DNAJC9 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr14:20,434,706...20,438,978
Ensembl chr14:20,434,706...20,438,978
|
|
G |
Ephx1 |
epoxide hydrolase 1, microsomal |
decreases expression multiple interactions |
ISO |
Atazanavir Sulfate results in decreased expression of EPHX1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469
|
|
G |
Fkbp5 |
FK506 binding protein 5 |
multiple interactions decreases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA Atazanavir Sulfate results in decreased expression of FKBP5 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501
|
|
G |
Fmo1 |
flavin containing monooxygenase 1 |
decreases expression |
ISO |
Atazanavir Sulfate results in decreased expression of FMO1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179
|
|
G |
Fosl1 |
fos-like antigen 1 |
multiple interactions increases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA Atazanavir Sulfate results in increased expression of FOSL1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr X:100,419,982...100,429,235
Ensembl chr X:100,419,984...100,429,235
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA |
CTD |
PMID:33819548 |
|
NCBI chr X:84,745,543...84,820,425
Ensembl chr X:84,745,543...84,820,425
|
|
G |
Gprc5b |
G protein-coupled receptor, family C, group 5, member B |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:118,571,263...118,594,434
Ensembl chr 7:118,571,270...118,594,434
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions decreases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA Atazanavir Sulfate results in decreased expression of GPX2 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
|
|
G |
Gsta3 |
glutathione S-transferase, alpha 3 |
multiple interactions decreases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA Atazanavir Sulfate results in decreased expression of GSTA3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:21,310,837...21,335,885
Ensembl chr 1:21,310,813...21,335,885
|
|
G |
Gstm4 |
glutathione S-transferase, mu 4 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 3:107,937,887...107,952,495
Ensembl chr 3:107,947,724...107,952,210
|
|
G |
Hacl1 |
2-hydroxyacyl-CoA lyase 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:31,329,183...31,364,201
Ensembl chr14:31,320,687...31,363,243
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Atazanavir Sulfate promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin]; Ritonavir promotes the reaction [Atazanavir Sulfate results in increased expression of HMOX1 mRNA] Atazanavir Sulfate results in increased expression of HMOX1 mRNA; Atazanavir Sulfate results in increased expression of HMOX1 protein |
CTD |
PMID:26968795 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hpx |
hemopexin |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:105,240,818...105,249,323
Ensembl chr 7:105,240,820...105,249,344
|
|
G |
Hspa5 |
heat shock protein 5 |
decreases expression multiple interactions |
ISO |
Atazanavir Sulfate results in decreased expression of HSPA5 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Atazanavir Sulfate results in increased expression of ICAM1 protein |
CTD |
PMID:26968795 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815
|
|
G |
Ifi204 |
interferon activated gene 204 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI16 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:173,574,859...173,594,606
Ensembl chr 1:173,574,859...173,594,509
|
|
G |
Ifi27 |
interferon, alpha-inducible protein 27 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:103,400,448...103,406,504
Ensembl chr12:103,400,470...103,406,498
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Jund |
jun D proto-oncogene |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 8:71,150,389...71,153,265
Ensembl chr 8:71,151,599...71,153,265
|
|
G |
Kynu |
kynureninase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:43,445,270...43,572,734
Ensembl chr 2:43,445,341...43,572,734
|
|
G |
Lbp |
lipopolysaccharide binding protein |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:158,148,413...158,174,772
Ensembl chr 2:158,148,413...158,174,772
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lipc |
lipase, hepatic |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:16,758,680...16,779,829
Ensembl chr 1:16,758,275...16,779,835
|
|
G |
Maff |
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) |
increases expression multiple interactions |
ISO |
Atazanavir Sulfate results in increased expression of MAFF mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA |
CTD |
PMID:32152650 |
|
NCBI chr15:79,230,813...79,243,278
Ensembl chr15:79,230,821...79,243,276
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA Atazanavir Sulfate results in increased expression of MAP1LC3B mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
decreases expression multiple interactions |
ISO |
Atazanavir Sulfate results in decreased expression of MAP2K6 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr11:110,289,928...110,416,348
Ensembl chr11:110,289,948...110,416,348
|
|
G |
Mapkapk3 |
mitogen-activated protein kinase-activated protein kinase 3 |
multiple interactions increases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA Atazanavir Sulfate results in increased expression of MAPKAPK3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 9:107,132,125...107,167,082
Ensembl chr 9:107,132,126...107,167,076
|
|
G |
Mlkl |
mixed lineage kinase domain-like |
multiple interactions increases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA Atazanavir Sulfate results in increased expression of MLKL mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 8:112,037,879...112,065,081
Ensembl chr 8:112,038,429...112,064,809
|
|
G |
Mmut |
methylmalonyl-Coenzyme A mutase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:41,245,576...41,272,880
Ensembl chr17:41,245,576...41,272,879
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729
|
|
G |
Nfxl1 |
nuclear transcription factor, X-box binding-like 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:72,670,647...72,717,078
Ensembl chr 5:72,670,644...72,717,027
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression multiple interactions |
ISO |
Atazanavir Sulfate results in decreased expression of NR1H4 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
decreases expression multiple interactions |
ISO |
Atazanavir Sulfate results in decreased expression of NR1I2 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions decreases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA Atazanavir Sulfate results in decreased expression of NR1I3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270
|
|
G |
Pah |
phenylalanine hydroxylase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:87,357,657...87,419,999
Ensembl chr10:87,357,657...87,419,998
|
|
G |
Pik3c2g |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma |
decreases expression multiple interactions |
ISO |
Atazanavir Sulfate results in decreased expression of PIK3C2G mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 6:139,591,070...139,915,010
Ensembl chr 6:139,564,219...139,915,010
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions decreases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA Atazanavir Sulfate results in decreased expression of PIK3R1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725
|
|
G |
Pon1 |
paraoxonase 1 |
decreases activity |
ISO |
Atazanavir Sulfate results in decreased activity of PON1 protein |
CTD |
PMID:27378623 |
|
NCBI chr 6:5,168,101...5,193,824
Ensembl chr 6:5,168,090...5,193,946
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Ppp1r3c |
protein phosphatase 1, regulatory subunit 3C |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:36,709,131...36,714,004
Ensembl chr19:36,709,131...36,714,053
|
|
G |
Rala |
v-ral simian leukemia viral oncogene A (ras related) |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA |
CTD |
PMID:32152650 |
|
NCBI chr13:18,055,160...18,118,802
Ensembl chr13:18,055,156...18,118,824
|
|
G |
Reep5 |
receptor accessory protein 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:34,477,938...34,508,044
Ensembl chr18:34,477,938...34,507,123
|
|
G |
Ripk1 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr13:34,181,072...34,219,153
Ensembl chr13:34,186,346...34,221,130
|
|
G |
Scp2 |
sterol carrier protein 2, liver |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:107,901,027...108,002,168
Ensembl chr 4:107,901,036...108,002,195
|
|
G |
Sdc2 |
syndecan 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:32,920,869...33,034,867
Ensembl chr15:32,920,869...33,035,081
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
increases expression multiple interactions |
ISO |
Atazanavir Sulfate results in increased expression of SERPINE1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Sh3glb1 |
SH3-domain GRB2-like B1 (endophilin) |
increases expression multiple interactions |
ISO |
Atazanavir Sulfate results in increased expression of SH3GLB1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 3:144,389,426...144,426,186
Ensembl chr 3:144,389,439...144,426,096
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
multiple interactions decreases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA Atazanavir Sulfate results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slc17a1 |
solute carrier family 17 (sodium phosphate), member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr13:24,051,607...24,079,713
Ensembl chr13:24,051,733...24,079,713
|
|
G |
Slc22a1 |
solute carrier family 22 (organic cation transporter), member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716
|
|
G |
Slc51a |
solute carrier family 51, alpha subunit |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA |
CTD |
PMID:32152650 |
|
NCBI chr16:32,294,396...32,306,697
Ensembl chr16:32,293,322...32,306,697
|
|
G |
Slc51b |
solute carrier family 51, beta subunit |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 9:65,320,035...65,330,055
Ensembl chr 9:65,319,996...65,330,237
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
increases expression multiple interactions |
ISO |
Atazanavir Sulfate results in increased expression of SOD2 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sorl1 |
sortilin-related receptor, LDLR class A repeats-containing |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:41,876,005...42,035,593
Ensembl chr 9:41,876,016...42,035,593
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions |
ISO |
Atazanavir Sulfate results in increased expression of SQSTM1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Srp72 |
signal recognition particle 72 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:77,122,548...77,147,782
Ensembl chr 5:77,122,530...77,147,784
|
|
G |
Sult2a1 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 |
multiple interactions decreases expression |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA Atazanavir Sulfate results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 7:13,530,171...13,571,335
Ensembl chr 7:13,530,171...13,571,334
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:84,263,199...84,307,119
Ensembl chr 2:84,263,199...84,307,119
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:70,004,921...70,021,860
Ensembl chr14:70,004,921...70,021,860
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
|
G |
Slc22a6 |
solute carrier family 22 (organic anion transporter), member 6 |
multiple interactions |
ISO |
cefoselis inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:16098483 |
|
NCBI chr19:8,595,360...8,605,663
Ensembl chr19:8,595,403...8,605,663
|
|
G |
Slc22a8 |
solute carrier family 22 (organic anion transporter), member 8 |
increases uptake multiple interactions |
ISO |
SLC22A8 protein results in increased uptake of cefoselis cefoselis inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:16098483 |
|
NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
decreases expression decreases activity |
ISO |
Erythromycin Estolate results in decreased expression of ABCB11 mRNA Erythromycin Estolate results in decreased activity of ABCB11 protein |
CTD |
PMID:17522070 PMID:20829430 PMID:23956101 PMID:28437613 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ABCB1 mRNA; Erythromycin Estolate results in increased expression of ABCB1A mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ABCC3 mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ABCG5 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ABCG8 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761
|
|
G |
Acadm |
acyl-Coenzyme A dehydrogenase, medium chain |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of ACADM mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:153,627,990...153,650,280
Ensembl chr 3:153,627,994...153,650,269
|
|
G |
Acly |
ATP citrate lyase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of ACLY mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:100,367,178...100,418,826
Ensembl chr11:100,367,179...100,418,826
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of ACSL1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 8:46,924,214...46,989,088
Ensembl chr 8:46,924,074...46,989,088
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase family 1, subfamily A1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase family 3, subfamily A2 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of ALDH3A2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:61,114,240...61,158,267
Ensembl chr11:61,114,243...61,158,290
|
|
G |
Apex1 |
apurinic/apyrimidinic endonuclease 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of APEX1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr14:51,162,406...51,164,645
Ensembl chr14:51,162,425...51,164,596
|
|
G |
Aspm |
abnormal spindle microtubule assembly |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of ASPM mRNA Erythromycin Estolate results in increased expression of ASPM mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:139,381,450...139,421,826
Ensembl chr 1:139,382,510...139,421,829
|
|
G |
Aurkb |
aurora kinase B |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of AURKB mRNA Erythromycin Estolate results in decreased expression of AURKB mRNA |
CTD |
PMID:24412560 |
|
NCBI chr11:68,936,477...68,942,490
Ensembl chr11:68,936,473...68,942,490
|
|
G |
Bax |
BCL2-associated X protein |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of BAX mRNA |
CTD |
PMID:12883083 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of BCL2 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of BTG2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:134,002,603...134,006,893
Ensembl chr 1:134,002,908...134,006,858
|
|
G |
Cacna1i |
calcium channel, voltage-dependent, alpha 1I subunit |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CACNA1I mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:80,171,439...80,282,493
Ensembl chr15:80,171,439...80,282,480
|
|
G |
Calu |
calumenin |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CALU mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 6:29,348,105...29,376,674
Ensembl chr 6:29,348,068...29,377,109
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CAR1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:14,831,274...14,873,425
Ensembl chr 3:14,831,276...14,873,428
|
|
G |
Cat |
catalase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CAT mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CCN2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccna2 |
cyclin A2 |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of CCNA2 mRNA Erythromycin Estolate results in decreased expression of CCNA2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of CCNB1 mRNA Erythromycin Estolate results in increased expression of CCNB1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of CDCA3 mRNA Erythromycin Estolate results in increased expression of CDCA3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:124,806,533...124,810,664
Ensembl chr 6:124,806,510...124,810,664
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of CDK1 mRNA Erythromycin Estolate results in decreased expression of CDK1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CEACAM1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:25,161,127...25,177,072
Ensembl chr 7:25,161,132...25,177,028
|
|
G |
Cenpw |
centromere protein W |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of CENPW mRNA Erythromycin Estolate results in decreased expression of CENPW mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:30,072,005...30,076,599
Ensembl chr10:30,070,565...30,076,556
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CES2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:105,727,462...105,747,042
Ensembl chr 8:105,727,485...105,747,810
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CHD2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 7:73,076,400...73,191,494
Ensembl chr 7:73,076,386...73,191,578
|
|
G |
Ctsl |
cathepsin L |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CTSL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr13:64,509,704...64,518,586
Ensembl chr13:64,507,151...64,518,704
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CYB5R3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr15:83,037,696...83,060,641
Ensembl chr15:83,037,695...83,056,793
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CYP1A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CYP3A9 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Cyp8b1 |
cytochrome P450, family 8, subfamily b, polypeptide 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CYP8B1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of DDIT3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Dut |
deoxyuridine triphosphatase |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of DUT mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:125,089,168...125,100,969
Ensembl chr 2:125,089,110...125,100,528
|
|
G |
Ect2 |
ect2 oncogene |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of ECT2 mRNA Erythromycin Estolate results in increased expression of ECT2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:27,151,371...27,207,971
Ensembl chr 3:27,151,371...27,208,027
|
|
G |
Fabp1 |
fatty acid binding protein 1, liver |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of FABP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 6:71,176,863...71,182,018
Ensembl chr 6:71,176,811...71,182,007
|
|
G |
Fads1 |
fatty acid desaturase 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of FADS1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr19:10,160,245...10,174,238
Ensembl chr19:10,160,252...10,174,241
|
|
G |
Fam111a |
family with sequence similarity 111, member A |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of FAM111A mRNA Erythromycin Estolate results in decreased expression of FAM111A mRNA |
CTD |
PMID:24412560 |
|
NCBI chr19:12,550,874...12,567,133
Ensembl chr19:12,523,104...12,567,132
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of FASN mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of FGA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:82,933,460...82,940,934
Ensembl chr 3:82,933,383...82,940,934
|
|
G |
Fgb |
fibrinogen beta chain |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of FGB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:82,949,553...82,957,170
Ensembl chr 3:82,947,448...82,957,170
|
|
G |
Fmo1 |
flavin containing monooxygenase 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of FMO1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of G6PC1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible 45 alpha |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of GADD45A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441
|
|
G |
Gck |
glucokinase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of GCK mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of GPX1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of GPX2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of GSTM3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:107,803,240...107,806,002
Ensembl chr 3:107,803,137...107,806,002
|
|
G |
Hibadh |
3-hydroxyisobutyrate dehydrogenase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of HIBADH mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 6:52,523,215...52,617,285
Ensembl chr 6:52,523,213...52,617,374
|
|
G |
Hmmr |
hyaluronan mediated motility receptor (RHAMM) |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of HMMR mRNA Erythromycin Estolate results in decreased expression of HMMR mRNA |
CTD |
PMID:24412560 |
|
NCBI chr11:40,592,215...40,624,290
Ensembl chr11:40,592,222...40,624,249
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of IGF2R mRNA |
CTD |
PMID:24412560 |
|
NCBI chr17:12,901,293...12,988,593
Ensembl chr17:12,901,293...12,988,551
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of IGFBP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of IGFBP2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:72,863,650...72,891,633
Ensembl chr 1:72,863,662...72,891,633
|
|
G |
Ip6k2 |
inositol hexaphosphate kinase 2 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of IP6K2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 9:108,660,928...108,683,532
Ensembl chr 9:108,660,995...108,683,536
|
|
G |
Isy1 |
ISY1 splicing factor homolog |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ISY1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:87,795,429...87,815,723
Ensembl chr 6:87,791,251...87,815,780
|
|
G |
Kif20b |
kinesin family member 20B |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of KIF20B mRNA Erythromycin Estolate results in decreased expression of KIF20B mRNA |
CTD |
PMID:24412560 |
|
NCBI chr19:34,899,735...34,953,150
Ensembl chr19:34,899,761...34,953,145
|
|
G |
Kif23 |
kinesin family member 23 |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of KIF23 mRNA Erythromycin Estolate results in decreased expression of KIF23 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 9:61,824,559...61,854,078
Ensembl chr 9:61,823,187...61,854,056
|
|
G |
Kif2c |
kinesin family member 2C |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of KIF2C mRNA Erythromycin Estolate results in increased expression of KIF2C mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:117,016,830...117,039,821
Ensembl chr 4:117,016,836...117,039,836
|
|
G |
Krt18 |
keratin 18 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of KRT18 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr15:101,936,651...101,940,461
Ensembl chr15:101,936,615...101,940,462
|
|
G |
Lbp |
lipopolysaccharide binding protein |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of LBP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:158,148,413...158,174,772
Ensembl chr 2:158,148,413...158,174,772
|
|
G |
Lgals3 |
lectin, galactose binding, soluble 3 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of LGALS3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr14:47,611,317...47,623,624
Ensembl chr14:47,605,208...47,623,617
|
|
G |
Lipc |
lipase, hepatic |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of LIPC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508
|
|
G |
Lpin1 |
lipin 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of LPIN1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:16,585,670...16,697,020
Ensembl chr12:16,585,670...16,696,967
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of LPL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Maob |
monoamine oxidase B |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of MAOB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:16,575,520...16,683,605
Ensembl chr X:16,575,521...16,683,605
|
|
G |
Mir16-2 |
microRNA 16-2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of MIR16 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:68,917,235...68,917,329
Ensembl chr 3:68,917,235...68,917,329
|
|
G |
Myc |
myelocytomatosis oncogene |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of MYC mRNA Erythromycin Estolate results in decreased expression of MYC mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Ncaph |
non-SMC condensin I complex, subunit H |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of NCAPH mRNA Erythromycin Estolate results in increased expression of NCAPH mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:126,945,729...126,975,857
Ensembl chr 2:126,945,729...126,975,874
|
|
G |
Nfkbib |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of NFKBIB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:28,457,676...28,466,069
Ensembl chr 7:28,457,676...28,466,937
|
|
G |
Noct |
nocturnin |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of NOCT mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:51,131,868...51,159,075
Ensembl chr 3:51,131,868...51,159,065
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of NUSAP1 mRNA Erythromycin Estolate results in decreased expression of NUSAP1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:119,449,205...119,480,646
Ensembl chr 2:119,448,779...119,481,725
|
|
G |
Otc |
ornithine transcarbamylase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of OTC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:10,118,584...10,187,275
Ensembl chr X:10,118,544...10,187,263
|
|
G |
Pclaf |
PCNA clamp associated factor |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of PCLAF mRNA Erythromycin Estolate results in decreased expression of PCLAF mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 9:65,797,605...65,810,833
Ensembl chr 9:65,797,519...65,810,548
|
|
G |
Pcmtd1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PCMTD1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:7,157,301...7,243,852
Ensembl chr 1:7,159,144...7,243,852
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase, isoenzyme 4 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PDK4 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309
|
|
G |
Per1 |
period circadian clock 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PER1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr11:68,985,934...69,000,791
Ensembl chr11:68,986,043...69,000,786
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PFKFB3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:11,476,241...11,558,882
Ensembl chr 2:11,476,244...11,558,888
|
|
G |
Pklr |
pyruvate kinase liver and red blood cell |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PKLR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:89,043,429...89,054,122
Ensembl chr 3:89,043,449...89,054,091
|
|
G |
Pygl |
liver glycogen phosphorylase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PYGL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr12:70,237,589...70,274,457
Ensembl chr12:70,237,585...70,278,262
|
|
G |
Rad51 |
RAD51 recombinase |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of RAD51 mRNA Erythromycin Estolate results in decreased expression of RAD51 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:118,943,295...118,966,554
Ensembl chr 2:118,943,274...118,977,926
|
|
G |
Rrm2 |
ribonucleotide reductase M2 |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of RRM2 mRNA Erythromycin Estolate results in increased expression of RRM2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:24,758,253...24,764,145
Ensembl chr12:24,758,240...24,764,145
|
|
G |
S100a8 |
S100 calcium binding protein A8 (calgranulin A) |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of S100A8 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342
|
|
G |
S100a9 |
S100 calcium binding protein A9 (calgranulin B) |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of S100A9 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028
|
|
G |
Serpina7 |
serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of SERPINA7 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr X:137,979,998...137,985,985
Ensembl chr X:137,980,006...137,985,985
|
|
G |
Sertad3 |
SERTA domain containing 3 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of SERTAD3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 7:27,173,265...27,176,789
Ensembl chr 7:27,173,193...27,176,789
|
|
G |
Shcbp1 |
Shc SH2-domain binding protein 1 |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of SHCBP1 mRNA Erythromycin Estolate results in increased expression of SHCBP1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:4,785,976...4,829,549
Ensembl chr 8:4,785,976...4,829,567
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of SLC38A2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:96,585,267...96,597,609
Ensembl chr15:96,585,273...96,597,611
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of SLCO1A4 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of SLCO1B2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Spc25 |
SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of SPC25 mRNA Erythromycin Estolate results in decreased expression of SPC25 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:69,009,753...69,036,583
Ensembl chr 2:69,024,239...69,036,538
|
|
G |
Spink1 |
serine peptidase inhibitor, Kazal type 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of SPINK1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr18:43,861,134...43,870,302
Ensembl chr18:43,861,147...43,870,622
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of SREBF1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of STAT3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of STYXL1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:135,776,074...135,807,277
Ensembl chr 5:135,776,074...135,807,239
|
|
G |
Sugt1 |
SGT1, suppressor of G2 allele of SKP1 (S. cerevisiae) |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of SUGT1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr14:79,825,100...79,868,237
Ensembl chr14:79,825,131...79,872,636
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TGFB3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:86,103,517...86,125,815
Ensembl chr12:86,103,519...86,125,815
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of THRSP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:97,062,140...97,066,757
Ensembl chr 7:97,062,145...97,066,937
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of TIMP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tmcc1 |
transmembrane and coiled coil domains 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TMCC1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:115,995,572...116,170,485
Ensembl chr 6:115,995,572...116,170,447
|
|
G |
Tnfaip3 |
tumor necrosis factor, alpha-induced protein 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TNFAIP3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:18,876,658...18,891,158
Ensembl chr10:18,876,658...18,891,405
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Trp53 |
transformation related protein 53 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TP53 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TSC22D3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr X:139,440,277...139,501,257
Ensembl chr X:139,440,277...139,501,408
|
|
G |
Ttr |
transthyretin |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TTR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr18:20,797,266...20,807,383
Ensembl chr18:20,798,337...20,807,378
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TXNRD1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
|
|
G |
Ugt2a1 |
UDP glucuronosyltransferase 2 family, polypeptide A1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of UGT2A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:87,607,349...87,638,730
Ensembl chr 5:87,607,349...87,638,730
|
|
G |
Zc3h13 |
zinc finger CCCH type containing 13 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ZC3H13 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr14:75,521,746...75,581,873
Ensembl chr14:75,521,813...75,581,866
|
|
G |
Zfp354a |
zinc finger protein 354A |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of ZFP354A mRNA |
CTD |
PMID:24412560 |
|
NCBI chr11:50,950,052...50,963,626
Ensembl chr11:50,950,084...50,963,626
|
|
G |
Zfp574 |
zinc finger protein 574 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ZFP574 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 7:24,775,099...24,782,917
Ensembl chr 7:24,771,992...24,782,917
|
|